Viral hepatitis and liver cancer by Centers for Disease Control and Prevention (U.S.)
   
   
   
   
   
   
   
   
MARCH 2016
U.S. Department of Health and Human Services




Viral Hepatitis and 
Liver Cancer
In March 2016, the Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer 
Institute, and the North American Association of Central Cancer Registries released their Annual Report to the Nation  
on the Status of Cancer, 1975 – 2012 (ARN). 
The report shows, in contrast to most other cancers in the U.S., liver 
cancer incidence is increasing at a rapid rate (2.3 percent per year  
overall from 2003 – 2012) – second only to thyroid cancer – and the  
rate of deaths due to liver cancer is increasing faster than for any other 
type of cancer.
Hepatitis B and C are major contributing factors to liver cancer – 
underscoring the critical importance of hepatitis prevention and 
treatment. The most recent U.S. cancer data show:
Liver cancer increased 72 percent between 2003 – 2012  
(16,265 to 28,012)  
Almost 23,000 people died from liver cancer in 2012, a 56 percent 
increase in deaths since 2003  
The ARN indicates Hepatitis C and liver cancer-associated death rates 
were highest among baby boomers, born 1945 – 1965, who also 
represent the vast majority of Americans with hepatitis C infection 
Factors Contributing to Liver 
Cancer Incidence in the U.S.
Some Populations are Particularly Affected by Viral Hepatitis 
and Liver Cancer 
People with hepatitis B and hepatitis C have the greatest risk of liver cancer. In the U.S., approximately 65 percent of  
liver cancer cases are related to hepatitis B or C, with nearly 50 percent attributable to hepatitis C alone. Some groups  
of Americans are at increased risk for chronic viral hepatitis infection.
Hepatitis C
Approximately 3.5 million Americans are living with chronic 
hepatitis C infection 
More than 75 percent are baby boomers, many of whom were 
unknowingly infected before hepatitis C was discovered  
in 1989
Overall prevalence of hepatitis C among baby boomers is six 
times that of other adults
Because hepatitis C has been silently damaging their livers 
for many years, baby boomers are particularly vulnerable to 
cirrhosis and liver cancer
More recently, troubling increases in the rate of new hepatitis C 
infections related to injection drug use have occurred among 
young people in some parts of the country
81% of American adults with 
hepatitis C are baby boomers
Hepatitis B
   As many as 2.2 million Americans are living with 
hepatitis B
   Hepatitis B disproportionately affects Asian Americans 
and Pacific Islanders (AAPIs) – while AAPIs make up less 
than 5 percent of the U.S. population, they account for 
more than 50 percent of Americans with hepatitis B
   AAPIs have historically been the racial/ethnic group 
most affected by liver cancer
Hepatitis B and C are 
Preventable and Treatable 
While there is currently no vaccine to prevent hepatitis 
C infection, highly effective treatment options are 
now available that can cure over 85 percent of cases. 
However, because hepatitis C initially has few noticeable 
symptoms, at least half of those infected don’t know 
it. For years, even decades, hepatitis C can slowly and 
silently damage the liver, leading to cancer and other 
serious health consequences.  
That’s why it is critical that everyone at risk for hepatitis C 
get screened. Once diagnosed, most hepatitis C cases can 
be cured in just a few months, and successful treatment 
reduces liver cancer risk by 75 percent. Diagnosis and 
treatment also helps decrease transmission of the virus 
to others. 
Screening and vaccinating individuals at high risk for 
hepatitis B is also critical. Like hepatitis C, most people 
living with hepatitis B are not aware of their infection, 
but detection and treatment can prevent serious liver 
damage, including reducing liver cancer risk between  
50 percent and 80 percent. Hepatitis B vaccination, now 
part of the standard infant vaccine schedule, is also safe 
and highly effective.
Benefits of Screening and 
Treatment Extend Beyond 
Cancer Prevention
Hepatitis screening and treatment not only helps prevent 
liver cancer, it protects people from a host of other 
health complications. Untreated chronic hepatitis causes 
long-term inflammation in the liver, which can eventually lead to liver scarring, cirrhosis, and other damage. Up to 1 in 5 
people with hepatitis C develop cirrhosis, and hepatitis C is the number one cause of liver transplants. But with increased 
screening and treatment, many of these complications could be prevented. Overall, diagnosis and treatment reduces the 
risk of all-cause mortality among individuals with hepatitis C by 50 percent. 
Ensuring individuals at risk have access to prevention, testing, and treatment could dramatically reduce the severe 
burden of viral hepatitis and drive down liver cancer incidence and death rates in the United States. 
MARCH 2016 2
Who Should Be Tested For Hepatitis C?
Age-based guidelines:
   All persons born from 1945 through 1965
Risk-based guidelines:
   Anyone who has ever injected illegal drugs
   Recipients of blood transfusions or solid organ 
transplants before July 1992, or clotting factor 
concentrates made before 1987
   Patients who have ever received long-term 
hemodialysis treatment
   Persons with known exposures to hepatitis C,  
such as:
        Health care workers after needlesticks 
involving blood from a patient with  
hepatitis C
        Recipients of blood or organs from a donor  
who later tested positive for hepatitis C
   People living with HIV
   People with signs or symptoms of liver disease  
(e.g., abnormal liver enzyme tests)
   Children born to mothers who have hepatitis C
Who Should Be Tested For Hepatitis B?
Testing for hepatitis B is recommended for certain 
groups of people, including:
   People born in Asia, Africa, and other regions  
with moderate or high rates of hepatitis B
   Unvaccinated people whose parents are from 
regions with high rates of hepatitis B
   Anyone having sex with a person infected with 
hepatitis B
   People who live with someone with hepatitis B
   Men who have sex with men
   People who inject drugs
   All pregnant women
   People with HIV infection
   People on hemodialysis
   People who receive chemotherapy or other 
types of immunosuppressive therapy
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Making the Most of Hepatitis C Treatment Advances
Today, the vast majority of hepatitis C infections can be cured, thanks to newly available and highly effective 
treatment options. But the benefit of new therapies cannot be fully realized unless patients have access to 
the medications. Hepatitis C screening remains the essential first step to diagnosis and treatment. But once 
diagnosed, individuals may face additional barriers to care. 
The newest and most effective hepatitis C treatments are also the most expensive. CDC studies have shown 
that treating all hepatitis C-infected persons using these newly available therapies is cost-effective from a 
societal perspective – on par with cervical cancer screening or cholesterol testing. However, the price of current 
medications is a formidable barrier for many. Continuing to explore ways to ensure that people have access to 
needed treatments, including for hepatitis C, is critical. 
While resource limitations may require some providers to prioritize certain patients for treatment, it is 
important that providers continue to do everything possible to follow the guidelines of the American 
Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America, which 
recommend treatment for all patients with chronic hepatitis C. 
Providing equitable access to testing, care, and treatment could dramatically reduce hepatitis C-related 
morbidity and mortality, stop transmission, and ultimately eliminate hepatitis C as a public health concern in 
the United States. 
If you are a member of the news media and need more information,  
please visit www.cdc.gov/nchhstp/Newsroom or contact the News Media Line at CDC’s National Center for HIV/AIDS,  
Viral Hepatitis, STD, and TB Prevention: 404-639-8895 or NCHHSTPMediaTeam@cdc.gov.
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